CS273606B2 - Method of 1,3-oxazolidine-2-onane's derivatives preparation - Google Patents

Method of 1,3-oxazolidine-2-onane's derivatives preparation Download PDF

Info

Publication number
CS273606B2
CS273606B2 CS392785A CS392785A CS273606B2 CS 273606 B2 CS273606 B2 CS 273606B2 CS 392785 A CS392785 A CS 392785A CS 392785 A CS392785 A CS 392785A CS 273606 B2 CS273606 B2 CS 273606B2
Authority
CS
Czechoslovakia
Prior art keywords
compound
oxazolidin
phenyl
formula
piperidinopropyl
Prior art date
Application number
CS392785A
Other languages
Czech (cs)
English (en)
Other versions
CS392785A2 (en
Inventor
Mitsuo Masaki
Haruhiko Shinozaki
Masaru Satoh
Naoya Moritoh
Koichi Hashimoto
Toshiro Kamishiro
Original Assignee
Nipon Chemiphar Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nipon Chemiphar Co Ltd filed Critical Nipon Chemiphar Co Ltd
Priority to CS411486A priority Critical patent/CS273616B2/cs
Publication of CS392785A2 publication Critical patent/CS392785A2/cs
Publication of CS273606B2 publication Critical patent/CS273606B2/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CS392785A 1984-09-28 1985-05-31 Method of 1,3-oxazolidine-2-onane's derivatives preparation CS273606B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CS411486A CS273616B2 (en) 1984-09-28 1986-06-04 Method of 1,3-oaazolidine-2-onane's derivatives preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59203624A JPS6183170A (ja) 1984-09-28 1984-09-28 新規な１，３−オキサゾリジン−２−オン誘導体およびその製造法

Publications (2)

Publication Number Publication Date
CS392785A2 CS392785A2 (en) 1990-08-14
CS273606B2 true CS273606B2 (en) 1991-03-12

Family

ID=16477122

Family Applications (1)

Application Number Title Priority Date Filing Date
CS392785A CS273606B2 (en) 1984-09-28 1985-05-31 Method of 1,3-oxazolidine-2-onane's derivatives preparation

Country Status (27)

Country Link
US (1) US4644063A (nl)
JP (1) JPS6183170A (nl)
KR (1) KR900004323B1 (nl)
AR (1) AR240924A1 (nl)
AT (1) AT392069B (nl)
AU (1) AU566419B2 (nl)
BR (1) BR8502707A (nl)
CA (1) CA1252092A (nl)
CH (1) CH663207A5 (nl)
CS (1) CS273606B2 (nl)
DE (1) DE3519261C2 (nl)
DK (1) DK165952C (nl)
ES (2) ES8800571A1 (nl)
FR (1) FR2571052B1 (nl)
GB (2) GB8512975D0 (nl)
HU (1) HU199132B (nl)
IN (1) IN162060B (nl)
IT (1) IT1208807B (nl)
MX (2) MX161397A (nl)
MY (1) MY102081A (nl)
NL (1) NL193191C (nl)
NZ (1) NZ212143A (nl)
PH (1) PH20852A (nl)
RO (1) RO91422B (nl)
SE (1) SE463100B (nl)
SU (2) SU1402263A3 (nl)
ZA (1) ZA854001B (nl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6183147A (ja) * 1984-09-28 1986-04-26 Nippon Chemiphar Co Ltd 新規なアミノアルコール誘導体およびその製造法並びにそれを有効成分とするグルタミン酸遮断剤
JPH0759570B2 (ja) * 1986-05-06 1995-06-28 三井東圧化学株式会社 ２−オキサゾリジノン類の製造方法
JPH0713017B2 (ja) * 1986-06-18 1995-02-15 日本ケミファ株式会社 脳細胞保護作用を有する医薬組成物
DE3877470T2 (de) * 1987-09-10 1993-06-24 Merck Sharp & Dohme Oxazole und thiazole zur behandlung seniler demenz.
ATE106243T1 (de) * 1988-03-24 1994-06-15 Sankyo Co Verwendung von isoxazolinonen als cerebro-aktive medikamente.
JPH0314562A (ja) * 1988-04-11 1991-01-23 Nippon Chemiphar Co Ltd 新規なアルキレンジアミン誘導体およびグルタミン酸遮断剤
US5187171A (en) * 1989-01-09 1993-02-16 G. D. Searle & Co. Use of a glycine b partial agonist as an antipsychotic
ATE170516T1 (de) * 1992-07-14 1998-09-15 Nippon Chemiphar Co Alkylendiaminderivate
US5698573A (en) * 1993-09-15 1997-12-16 Merck, Sharp & Dohme, Ltd. Imidazolone and oxazolone derivatives as dopamine antagonists
DE4425613A1 (de) * 1994-07-20 1996-01-25 Bayer Ag 5-gliedrige Heteroaryl-oxazolidinone
US6037354A (en) * 1997-06-18 2000-03-14 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US9717239B2 (en) 2013-03-14 2017-08-01 Akzo Nobel Chemicals International B.V. Cellulose ether as a drift control agent and rainfastness agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2437389A (en) * 1948-03-09 Oxazoeidones and erocesstok
DE1135461B (de) * 1959-05-08 1962-08-30 Knoll Ag Verfahren zur Herstellung von basisch substituierten Phthalimidinen
FR1301267A (fr) * 1961-04-04 1962-08-17 Science Union Et Compagnie Soc Nouveaux dérivés de l'oxazolidinone-2 et leurs procédés de préparation
US3131197A (en) * 1963-03-13 1964-04-28 Smith Kline French Lab 5-(3, 4-carbonyldioxyphenyl)-3-isopropyl-2-oxazolidone
US3576808A (en) * 1967-09-15 1971-04-27 Miles Lab N-4-phenyl-1-piperazinylalkyl-5-phenyl-oxazolidinones
GB1222708A (en) * 1968-10-22 1971-02-17 Delalande Sa Novel 5-(n-substituted aminomethyl)-2-oxazolidinones and their process of preparation
FR2179582B1 (nl) * 1972-04-13 1975-10-10 Synthelabo

Also Published As

Publication number Publication date
ES557075A0 (es) 1988-04-01
GB2165237A (en) 1986-04-09
ATA165685A (de) 1990-07-15
HUT39168A (en) 1986-08-28
AU4469785A (en) 1986-04-10
PH20852A (en) 1987-05-19
JPH0469150B2 (nl) 1992-11-05
GB8512975D0 (en) 1985-06-26
JPS6183170A (ja) 1986-04-26
IT8567500A0 (it) 1985-05-30
NL8501579A (nl) 1986-04-16
SU1431679A3 (ru) 1988-10-15
GB8513685D0 (en) 1985-07-03
RO91422A (ro) 1987-06-30
AU566419B2 (en) 1987-10-22
GB2165237B (en) 1987-12-09
US4644063A (en) 1987-02-17
ES8802152A1 (es) 1988-04-01
IT1208807B (it) 1989-07-10
AT392069B (de) 1991-01-25
SU1402263A3 (ru) 1988-06-07
DE3519261A1 (de) 1986-04-10
CH663207A5 (fr) 1987-11-30
AR240924A2 (es) 1991-03-27
CS392785A2 (en) 1990-08-14
DK165952B (da) 1993-02-15
KR900004323B1 (ko) 1990-06-22
HU199132B (en) 1990-01-29
MY102081A (en) 1992-03-31
KR860002502A (ko) 1986-04-26
DE3519261C2 (de) 1997-01-16
MX21592A (es) 1994-01-31
CA1252092A (en) 1989-04-04
NL193191B (nl) 1998-10-01
ES543517A0 (es) 1987-11-01
SE463100B (sv) 1990-10-08
MX161397A (es) 1990-09-20
NZ212143A (en) 1987-11-27
RO91422B (ro) 1987-07-02
DK230185A (da) 1986-03-29
NL193191C (nl) 1999-02-02
BR8502707A (pt) 1986-05-27
SE8502525L (sv) 1986-03-29
ZA854001B (en) 1986-01-29
DK165952C (da) 1993-07-05
FR2571052B1 (fr) 1988-03-04
FR2571052A1 (fr) 1986-04-04
IN162060B (nl) 1988-03-19
AR240924A1 (es) 1991-03-27
DK230185D0 (da) 1985-05-23
SE8502525D0 (sv) 1985-05-22
ES8800571A1 (es) 1987-11-01

Similar Documents

Publication Publication Date Title
KR890003424B1 (ko) 비사이클릭 아미노산 유도체의 제조방법
CA1120928A (en) Acetohydroxamic acids
DE69434991T2 (de) Substituierte Morpholinderivate und ihre Verwendung als Arzneimittel
US4714708A (en) Derivatives of cis, endo-2-azabicyclo[5.3.0]decane-3-carboxylic acid, and their use for treating hypertension
CS273606B2 (en) Method of 1,3-oxazolidine-2-onane's derivatives preparation
CS240954B2 (en) Preparation method of 1,2-dihydropyridines
FR2677984A1 (fr) Derives d'imidazoline n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
US4935419A (en) Novel 1-piperazinecarboxamide derivatives
PT89657B (pt) Processo de preparacao de derivados do imidazolo, dos seus intermediarios e de composicoes farmaceuticas contendo aqueles compostos
JP4428053B2 (ja) ガバペンチン若しくはプレガバリンおよびｎ型カルシウムチャンネル拮抗剤を含有する医薬組成物
JPH06104649B2 (ja) アミノ酸誘導体抗痙攣剤
FR2659323A1 (fr) Derives de 4-(aminomethyl) piperidine, leur preparation et leur application en therapeutique.
KR910002671B1 (ko) 아미노-알콜 유도체의 제조방법
MXPA02006033A (es) Nuevos derivados amino substituidos ramificados de 3-amino-1-fenil-1h[1,2,4]triazol, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
JPH01186866A (ja) 分割化アミノピロリジン神経防護剤
JP2655754B2 (ja) コレシストキニンレセプター拮抗剤としてのベンゾチアゼピン及びベンゾオキサゼピンの誘導体
DK169267B1 (da) 3-Aryloxyazetidincarboxamider, farmaceutiske præparater indeholdende disse forbindelser, fremgangsmåde til forbindelsernes fremstilling samt deres anvendelse til fremstilling af et farmaceutisk præparat til behandling af epilepsi og/eller konvulsioner
RU2298010C2 (ru) Производные дигидроимидазо[5,1-а]- бета-карболина, способ их получения и фармацевтическая композиция
HU200608B (en) Process for producing new dihydro-1,4.oxazino(2,3-a)quinoline derivatives and pharmaceutical compositions comprising such compounds
US4663319A (en) 3-(1,3-dithiol-2-ylidene)-2,4-dioxopyrrolidines, -piperidines, and -hexahydroazepines and use thereof against hepatic diseases
CS273616B2 (en) Method of 1,3-oaazolidine-2-onane's derivatives preparation
DE60118780T2 (de) Zur verwendung als procollagen-c-proteinase-inhibitoren geeignete 3-ox(adi)azolylpropanohydroxamsäuren
GB1565021A (en) Pharmaceutical compositions containing alkylamine deratives
NL7908030A (nl) Nieuwe chinolinederivaten en farmaceutische preparaten die een dergelijke verbinding bevatten, alsmede werk- wijze voor het bereiden van deze verbindingen.
FR2514354A1 (fr) Nouveaux derives de 5-aminoisoxazole et procedes de leur preparation